MA64631A1 - Procédé de production de capside modifié de virus adéno-associé - Google Patents

Procédé de production de capside modifié de virus adéno-associé

Info

Publication number
MA64631A1
MA64631A1 MA64631A MA64631A MA64631A1 MA 64631 A1 MA64631 A1 MA 64631A1 MA 64631 A MA64631 A MA 64631A MA 64631 A MA64631 A MA 64631A MA 64631 A1 MA64631 A1 MA 64631A1
Authority
MA
Morocco
Prior art keywords
associated virus
capsid
modified
producing modified
virus capsid
Prior art date
Application number
MA64631A
Other languages
English (en)
Inventor
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Anna Nikolaevna Strelkova
Pavel Mikhailovich Gershovich
Tatiana Evgenievna Shugaeva
Sergei Aleksandrovich Legotskii
Alexandr Anatolevich Nadolinskii
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA64631A1 publication Critical patent/MA64631A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte au domaine de la thérapie génique et de la biologie moléculaire. La présente invention concerne plus particulièrement un procédé de production de capside modifié de virus adéno-associé (aav) et un capside modifié de aav obtenu selon ce procédé, ainsi qu'un acide nucléique séparé codant ledit capside modifié, et un vecteur sur la base d'un virus adéno-associé recombinant pour administrer à un sujet une séquence hétérologue d'acide nucléique comprenant ledit capside modifié.
MA64631A 2021-08-20 2022-08-18 Procédé de production de capside modifié de virus adéno-associé MA64631A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021124731 2021-08-20
PCT/RU2022/050255 WO2023022631A1 (fr) 2021-08-20 2022-08-18 Procédé de production de capside modifié de virus adéno-associé

Publications (1)

Publication Number Publication Date
MA64631A1 true MA64631A1 (fr) 2024-05-31

Family

ID=85240917

Family Applications (1)

Application Number Title Priority Date Filing Date
MA64631A MA64631A1 (fr) 2021-08-20 2022-08-18 Procédé de production de capside modifié de virus adéno-associé

Country Status (11)

Country Link
EP (1) EP4389880A1 (fr)
CN (1) CN118139974A (fr)
AR (1) AR126841A1 (fr)
AU (1) AU2022328531A1 (fr)
CA (1) CA3229580A1 (fr)
CO (1) CO2024001768A2 (fr)
EC (1) ECSP24013031A (fr)
IL (1) IL310949A (fr)
MA (1) MA64631A1 (fr)
TW (1) TW202317770A (fr)
WO (1) WO2023022631A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431140A1 (de) 1984-08-24 1986-03-06 Behringwerke Ag, 3550 Marburg Enhancer fuer eukaryotische expressionssysteme
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP3693025B1 (fr) 2011-04-22 2021-10-13 The Regents of The University of California Virions de virus adéno-associé avec capside variant et procédés d'utilisation de ceux-ci
MY172457A (en) 2012-04-18 2019-11-26 Childrens Hospital Philadelphia Composition and methods for highly efficient gene transfer using aav capsid variants
CA3012711A1 (fr) * 2016-01-26 2017-08-03 Defensin Therapeutics Aps Procedes de modulation du microbiote intestinal
BR112020023393A2 (pt) * 2018-05-16 2021-02-09 Spark Therapeutics, Inc. cassetes de expressão de a-glicosidase ácida otimizados por códon e métodos de uso dos mesmos

Also Published As

Publication number Publication date
ECSP24013031A (es) 2024-03-01
AU2022328531A1 (en) 2024-03-14
EP4389880A1 (fr) 2024-06-26
AR126841A1 (es) 2023-11-22
IL310949A (en) 2024-04-01
CA3229580A1 (fr) 2023-02-23
CO2024001768A2 (es) 2024-07-08
TW202317770A (zh) 2023-05-01
WO2023022631A1 (fr) 2023-02-23
CN118139974A (zh) 2024-06-04

Similar Documents

Publication Publication Date Title
JP2020508685A5 (fr)
MA46230B1 (fr) Mutations de protéine d'enveloppe du vih stabilisant la forme trimère
BR112022023554A2 (pt) Composições e métodos de rna circular
JP7457832B2 (ja) Ｐｃｓｋ９の塩基編集および疾患の処置のためにこれを使用する方法
MA34738B1 (fr) Neutralisation d'anticorps anti-ccl20
DE69941059D1 (de) Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden
EA200301169A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ CD44v6
US10457631B2 (en) Biodegradable amino-ester nanomaterials for nucleic acid delivery
MA56142A1 (fr) Protéine modifiée séparée vp1 de capside de aav5
MA62178A1 (fr) Effet synergique de smn1 et mir-23a dans le traitement de l'amyotrophie spinale
MA64631A1 (fr) Procédé de production de capside modifié de virus adéno-associé
CN1646702A (zh) 用于治疗性寡核苷酸的蛋白质载体***
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
CO2022016956A2 (es) Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd)
MX2023007204A (es) Lipidos ionizables.
CA2470579A1 (fr) Production efficace de fragments f(ab')2 dans des cellules de mammiferes
FR3104976B1 (fr) Composition à base de rétinol
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
WO2023031392A3 (fr) Nouvelles nanoparticules lipidiques pour l'administration d'acides nucléiques comprenant de la phosphatidylsérine
MA64618A1 (fr) Protéine modifiée séparée vp1 de capside aav9
WO2004101801A3 (fr) Methode amelioree pour produire des preparations a base de vecteurs amplicon herpes virus non pathogenes, exemptes de virus auxiliaires, virus auxiliaire et cellules utilises selon cette methode, outils genetiques correspondants, et applications de ces vecteurs amplicon non pathogenes
CN1837191A (zh) 一种n－乙酰基半胱氨酸衍生物与应用
WO2023024500A1 (fr) Constructions et procédés de préparation d'arn circulaire
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
WO2002085287A3 (fr) Vecteurs adenoviraux minimaux pour immunisation